Ascendis Pharma A/S (ASND) News Today $245.85 +0.70 (+0.29%) Closing price 10/27/2026 04:00 PM EasternExtended Trading$249.48 +3.63 (+1.48%) As of 10/27/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Ascendis Pharma A/S Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Ascendis Pharma A/S (NASDAQ:ASND) Stock Moved Up to "Hold" by Canaccord Genuity GroupOctober 27 at 7:29 AM | marketbeat.comAscendis Pharma A/S $ASND Stock: Nisa Investment Advisors LLC Increases PositionOctober 27 at 4:32 AM | marketbeat.comAscendis Pharma A/S announces TransCon PTH pooled data showing kidney function improvements for up to 5 yearsOctober 26 at 8:14 PM | msn.comTransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 YearsOctober 26 at 3:07 PM | markets.businessinsider.comAscendis Pharma Says Trial Results Show 'Meaningful Improvements' in Kidney Function in Adults with HypoparathyroidismOctober 26 at 3:07 PM | marketscreener.comMAscendis Pharma A/S $ASND Shares Newly Bought by Inspire Investing LLCOctober 26 at 3:43 AM | marketbeat.comAscendis Pharma A/S $ASND Shares Purchased by Assenagon Asset Management S.A.October 21, 2026 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Stock Has Consensus Price Target of $309.26October 21, 2026 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Stock Has Consensus Price Target of $309.26 According to AnalystsOctober 21, 2026 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) & Generate Biomedicines (NASDAQ:GENB) Head-To-Head SurveyOctober 19, 2026 | americanbankingnews.comAscendis Pharma A/S Receives Positive CHMP Opinion Recommending Marketing Authorization For Once-Weekly TransCon CNP For The Treatment Of Achondroplasia In ChildrenOctober 17, 2026 | marketscreener.comMASND shares shrug off positive European opinion for FDA-approved achondroplasia drugOctober 17, 2026 | msn.comAscendis Pharma (ASND) Receives a New Rating from a Top AnalystOctober 16, 2026 | theglobeandmail.comAscendis Pharma's TransCon CNP Gets Positive EU Recommendation for Children With AchondroplasiaOctober 16, 2026 | finance.yahoo.comAscendis Pharma Receives Positive CHMP Opinion for EU Marketing Authorization of Once-Weekly TransCon CNP for AchondroplasiaOctober 16, 2026 | quiverquant.comQOnce-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in ChildrenOctober 16, 2026 | globenewswire.comRBC Capital Sticks to Its Buy Rating for Ascendis Pharma (ASND)October 16, 2026 | theglobeandmail.comBarclays Reaffirms Their Buy Rating on Ascendis Pharma (ASND)October 16, 2026 | theglobeandmail.comUBS Adjusts Ascendis Pharma A/S Price Target to $269 From $307, Maintains Buy RatingOctober 15, 2026 | marketscreener.comMAscendis Pharma A/S $ASND Shares Newly Purchased by Avior Wealth Management LLCOctober 15, 2026 | marketbeat.comAscendis Pharma A/S (NASDAQ:ASND) Stock Moved Up to "Buy" by Wall Street ZenOctober 10, 2026 | marketbeat.comAscendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026October 6, 2026 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Cytokinetics (CYTK)October 4, 2026 | theglobeandmail.comBioMarin Pharmaceutical Inc. And Ascendis Pharma A/S Enter Into Settlement And License AgreementOctober 1, 2026 | marketscreener.comMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (ASND), Lakefront Biotherapeutics (LKFT) and 10x Genomics (TXG)September 30, 2026 | theglobeandmail.comAscendis Pharma A/S's (ASND) "Overweight" Rating Reaffirmed at Cantor FitzgeraldSeptember 28, 2026 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Agilent (A), Ascendis Pharma (ASND)September 22, 2026 | theglobeandmail.comAscendis Pharma (ASND) Authorizes $400M Share BuybackSeptember 21, 2026 | finance.yahoo.comAscendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic ProgramsSeptember 19, 2026 | finance.yahoo.comAscendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?September 17, 2026 | finance.yahoo.comAscendis Pharma: Back To Full IndependenceSeptember 16, 2026 | seekingalpha.comAscendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comWhy Is Ascendis Pharma Stock Trading Lower on Tuesday?September 15, 2026 | benzinga.comAscendis Pharma Stock Falls 13% Over Share Repurchase Program AuthorizationSeptember 15, 2026 | rttnews.comAscendis Pharma Slides as Investors Weigh Novo Rights Reversion Despite BuybackSeptember 15, 2026 | quiverquant.comQThis Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For TuesdaySeptember 15, 2026 | benzinga.comAscendis Pharma: Ascendis to Regain Rights to TransCon Technology in Metabolic and Cardiovascular DiseasesSeptember 15, 2026 | finanznachrichten.deAscendis Pharma: Ascendis Announces Planned $400 Million Share Repurchase ProgramSeptember 15, 2026 | finanznachrichten.deAscendis Pharma A/S announces an Equity Buyback for $400 million worth of its shares.September 15, 2026 | marketscreener.comMAscendis Pharma Regains Rights to Obesity Drug, Discloses $400 Million Share BuybackSeptember 15, 2026 | finance.yahoo.comAscendis Unveils $400 Mln Buyback; Regains TransCon Rights From Novo NordiskSeptember 15, 2026 | rttnews.comOppenheimer Reaffirms Their Buy Rating on Ascendis Pharma (ASND)September 14, 2026 | theglobeandmail.comAscendis Pharma Authorizes Up to $400 Million Share Repurchase ProgramSeptember 14, 2026 | quiverquant.comQAscendis Pharma Regains Rights to TransCon Metabolic and Cardiovascular Programs, Including Once-Monthly TransCon SemaglutideSeptember 14, 2026 | quiverquant.comQAscendis Announces Planned $400 Million Share Repurchase ProgramSeptember 14, 2026 | globenewswire.comAscendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular DiseasesSeptember 14, 2026 | globenewswire.comMads Bodenhoff Sells 3,000 Shares of Ascendis Pharma A/S (NASDAQ:ASND) StockSeptember 10, 2026 | insidertrades.comFirst Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026September 9, 2026 | globenewswire.comAscendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceSeptember 8, 2026 | globenewswire.comAscendis Pharma In Focus Ahead Of Infant Achondroplasia Data At ESPE Congress 2026September 8, 2026 | rttnews.com Ascendis Pharma A/S Media Mentions By Week Ascendis Pharma A/S Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASND News Sentiment▼1.120.69▲Average Healthcare News Sentiment Ascendis Pharma A/S News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASND Articles This Week▼86▲ASND Articles Average Week Ascendis Pharma A/S Trends on MarketBeatThis week vs. last weekNew Followers2+100%Searches1Page Views2,599-17% Get Ascendis Pharma A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies ARGX News Today RVMD News Today BIIB News Today ALNY News Today ROIV News Today GMAB News Today INCY News Today UTHR News Today BNTX News Today INSM News Today News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Ascendis Pharma A/S dated 10/27/2026. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredYesterday's deadline changed everythingIn June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times th...Behind the Markets | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
